Inventor

LEGER OLIVIER

FR53 patents

⚠️ This page may combine multiple inventors who share the name “LEGER OLIVIER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

LEGER OLIVIER

NOVIMMUNE SA

Anti-CD3 antibodies and methods of use thereof

Anti-IL-6/IL-6R antibodies and methods of use thereof

Anti-IP-10 antibodies and methods of use thereof

Anti-interferon gamma antibodies and methods of use thereof

Neutralizing antibodies and methods of use thereof

Fc receptor-binding polypeptides with modified effector functions

Anti-interferon gamma antibodies and methods of use thereof

Anti-IL-6/IL-6R antibodies and methods of use thereof

Anti-CD3 antibodies and methods of use thereof

Anti-IL-6/IL-6R antibodies

Methods of treating autoimmune diseases using anti-IL6/IL-6R complex antibodies

Anti-CD3 antibodies and methods of use thereof

Neutralizing antibodies and methods of use thereof

Neutralizing antibodies and methods of use thereof

Anti-IL-6/IL-6R antibodies and methods of use thereof

Nucleic acid encoding and method of producing anti-IL-17A/IL-17F cross-reactive antibodies

Neutralizing antibodies and methods of use thereof

Neutralizing antibodies and methods of use thereof

Combining therapies targeting multiple toll-like receptors

MERCK PATENT GMBH

Anti-PD-L1 antibodies and uses thereof

Anti-PD-L1 antibodies and uses thereof

Anti-PD-L1 antibodies and uses thereof

Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same

Anti-PD-L1 antibodies and uses thereof

Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same

BIOMUNEX PHARMACEUTICALS

Stable multispecific antibodies

Binding molecules to CD38 and PD-L1

Binding molecules to CD38 and PD-L1

Polypeptide linker for preparing multispecific antibodies

Bispecific antibodies targeting EGFR and HER2

ELSON GREG

Neutralizing antibodies and methods of use thereof

Fc receptor-binding polypeptides with modified effector functions

Methods of using neutralizing anti-TLR4/MD2 antibodies

PF MEDICAMENT

Anti-IGF-IR antibodies and uses thereof

Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof

Anti-IGF-IR antibodies and uses thereof

GOETSCH LILIANE

Anti-IGF-IR antibodies and uses thereof

Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof

Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof

MASTERNAK KRZYSZTOF

Anti-IL-17A/IL-17F cross-reactive antibodies

Methods of treatment using anti-IL-17A/IL-17F cross-reactive antibodies

CALYPSO BIOTECH SA

Antibodies to IL-15

Antibodies to IL-15 and uses thereof

FISCHER NICOLAS

Human anti-IP-10 antibodies uses thereof

Anti-IP-10 antibodies and methods of use thereof

BOEHRINGER INGELHEIM INT

FAPα-specific antibody with improved producibility

MACH BERNARD

Anti-CD3 antibodies and methods of use thereof

FERLIN WALTER

Anti-IL6/IL-6R antibodies

ROMMELAERE HEIDI

Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and method of treatment using same

ARES TRADING SA

Monoclonal antibody directed against CXCR5